In the group of 19 participants who reported that asparaginase levels were monitored, 68.4% reported that testing was performed in all asparaginase‐treated patients, 21.1% only in patients with ALL, and 10.5% in lymphoma patients or in other situations. The gene discussed is ASPG; the disease is acute lymphoblastic leukemia.